Tablets | Soft-gel capsules | Liquid solution | I expect no major changes with the different formulations | |
---|---|---|---|---|
Interfering drugs may influence the stability of therapy. Which LT4 preparation is in your experience least likely to be subject to variable absorption? | 85 (54.1%) | 10 (6.4%) | 5 (3.2%) | 57 (36.3%) |
Which of the following preparations of LT4 would you prescribe in case of first diagnosis of hypothyroidism when the patient self-reports intolerance to various foods raising the possibility of celiac disease, malabsorption, lactose intolerance, or intolerance to common excipients | 89 (56.7%) | 20 (12.7%) | 12 (7.6%) | 36 (22.9%) |
Which of the following preparations of LT4 would you prescribe for a patient established on LT4 who has unexplained poor biochemical control of hypothyroidism? | 80 (50.9%) * | 18 (11.5%) | 11 (7.0%) | 48 (30.6%) |
Which of the following preparations of LT4 would you prescribe for a patient with poor biochemical control who is unable (due to busy lifestyle) to take LT4 fasted and separate from food/drink? | 76 (48.4%) | 17 (10.8%) | 17 (10.8%) | 47 (29.9%) |
Which of the following preparations of LT4 would you prescribe for a patient established on LT4 tablets who has good biochemical control of hypothyroidism but continues to have symptoms? | 81 (51.6%) * | 9 (5.7%) | 1 (0.6%) | 66 (42.0%) |